As of 30 June, analysts price predictions compiled by MarketBeats and long-term forecasts by Wallet Investor projected that the ABBV stock price could rise. Pessimistic target level: 151.42 Optimistic target level: 154.48 ABBV (ABBV) Monthly Stock Prediction for 2023 Full forecast for 2023 AbbVie forecast for this year Neuroscience looks highly promising too, and aesthetics capable of driving some respectable growth driven by old stager Botox. Only you can design whether Abbvie stock is the right investment for you. As such I have downgraded my own growth expectations in the forecasting table above, reducing annual growth from 7.5%, to just 2.5%, after forecasting for $5bn revenues in FY22 - down 7.5% year-on-year. Compare Top Brokerages Here. AbbVie stock forecast 2022 - 2025 - 2030 with analysis AbbVie stock stood at $162.110000610352 on 2022-03-31. forecast for 2023 is $159.42, forecast for 2024 is $156.65, forecast for 2025 is $139.68, forecast for 2026 is $124.48, Nineteen analysts predict that AbbVie's share price will increase in the coming year, reaching $165.00. This indicates that AbbVie will be able to sustain or increase its dividend. Psoriatic arthritis is also adding significantly to Skyrizi's momentum, where we are now approved in 54 countries. In the next year, analysts expect Free Cash Flow to reach $26.97B - an increase of 58.68%. Teliso V is an antibody drug conjugate and a c-Met inhibitor. Bringing RGX314 would be a coup for AbbVie although I am forecasting for only $2bn in peak revenues in 2030 as a hedge against the risk that this candidate does not make it to market on safety grounds. I'll also share some a forward income statement and discounted cash flow analysis that suggests the present value of AbbVie shares ought to trade as high as $176, implying that shares are presently discounted by as much as 18% to their true worth. I/we have a beneficial long position in the shares of ABBV, BMY either through stock ownership, options, or other derivatives. In this post I model AbbVie product sales to 2030 - including pipeline assets - and use discounted cash flow analysis to calculate a present day share price target. Abbvie has a strong pipeline of projects ahead, and has recently received US FDA approval of its ulcerative colitis drug Rinvoq. That is substantially higher than the 12% CAGR achieved between 2018 - 2022, although that period includes the additional revenues from Allergan. Based on an average daily volume of 5,600,000 shares, the days-to-cover ratio is currently 2.1 days. The firm earned $15.12 billion during the quarter, compared to the consensus estimate of $15.30 billion. target price for AbbVie stock based on DCF / EBITDA multiple analysis (my table and assumptions). A Warner Bros. If youre new to trading, then youve probably heard the wrong thing about optionsthat theyre risky, unpredictable, or difficult. I haven't included Epcoritamab sales in my forecasts this time, but I hope to adjust the table before Q3'22 results are announced. For the next nine years, the forecast is for Revenue to grow by 3.57%. Gonzalez has vigorously defended AbbVie against accusations of price manipulation, but the company is renowned for pushing drug prices up annually and should its powerful lobbies become less powerful in the face of external pressure, once again, the sector will start to look unattractive for investors. In February, a Phase 3 induction study saw positive top-line results. Please. My detailed modeling suggests there is 15-20% upside to look forward to in the short term and that ABBV stock remains a solid long-term buy opportunity for investors. Fortunately for AbbVie shareholders Gonzalez and his management team have had many more years than expected to prepare for Humira's Loss of Exclusivity ("LOE"), and it has never been the Pharma's ambition to build its business around a single, all-conquering but time-limited drug. Since then, however, the stock price has fallen 18% to its current price of $142.6. Read our dividend analysis for ABBV. What other stocks do shareholders of AbbVie own? Without the additional patents - >130 in total - Humira would have lost its market exclusivity in 2016, but having eventually lost protection in Europe, which has resulted in a sales decline from $6.3bn in 2018, to ~$2.7bn in 2022, Humira will finally face generic competition in the US from the beginning of this year. The company employs 50,000 workers across the globe. Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing. I wrote this article myself, and it expresses my own opinions. The companys full-year adjusted diluted EPS guidance excluded any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of the year, as both cannot be reliably forecasted. Free Stock Analysis Report: See The True Value of Any Stock, The Best Strategy For Your Small Trading Account. The company has a robust pipeline of new products that are in some stage of clinical trials. There is no mention of Women's Health in the Q2'22 earnings call or in the 10-Q submission to the SEC, or any of the drugs within it, yet the divisions have not (to the best of my knowledge) been sold, despite rumors it was put up for sale at ~$5bn. Receive regular, detailed analysis focused on biotech and healthcare stocks. AbbVie CEO Gonzalez told the audience at the JPM Healthcare conference that: We now have a little over 90% access for next year for Humira at parity. The ex-dividend date of this dividend is Thursday, April 13th. In this post, I will discuss Q2'22 results, as well as the long-term outlook for AbbVie based on the latest information, goals, risks, and financial modeling analysis, to try to establish a target price for AbbVie stock. And we remain confident in our ability to achieve total sales of more than $9 billion by 2029. Your current $100 investment may be up to $188.28 in 2028. All generate blockbuster <$1bn per annum sales - in Stelara's case >$9bn per annum, and in Enbrel's case, >$4.5bn. AbbVie does not have the funds to pursue any large M&A deals, but it does not need to either, given the strength of its pipeline and products. AbbVie Stock: ABBV Overview and Dividend Potential, Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor (ABBV), Analyst Confidence in Eli Lilly Boosted by Product Pipeline (ABBV), Johnson & Johnson: Taking The Bull By The Horns? I am modelling for AbbVie to grow revenues at a compound annual growth rate of ~5% between now and 2030 with growth accelerating in the latter half of the decade. AbbVie has been increasing its dividend for 51 years. It is important to do your own research, and remember that your decision to trade depends on your attitude to risk, your expertise in the market, the spread of your investment portfolio and how comfortable you feel about losing money. CNN Sans & 2016 Cable News Network. For the next eight years, the forecast is for Free Cash Flow to grow by . Neuroscience is one of AbbVie's most intriguing divisions and perhaps the hardest to model. AbbVie Stock Forecast 2022 - 2025 - 2030 | StockForecast.com GB Enjoy your holiday weekend and catch up on our most read stories this week. As we look beyond 2025, we expect combined sales for Skyrizi and Rinvoq to exceed the peak revenues achieved by Humira, which was more than $21 billion. 2022 Cable News Network. Over the years, AbbView Inc. has made numerous acquisitions. Ever since its split from Abbott Laboratories (ABT) in 2012 AbbVie (NYSE:ABBV) has delivered strong returns for investors - its stock price having risen overall from $30, to $149 per share at the time of writing - trading down slightly from its all-time high of >$160 achieved in early December last year. ET comments The company reported its first revenue for Botox competitor Daxxify. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. AbbVie has a P/B Ratio of 15.97. Remember that past performance is not a guarantee of future results and you should never invest more money than you can afford to lose. Whether these factors make ABBV a good investment for you or not will depend on your portfolio composition, investment goals and risk profile, among other factors. Armed with management's detailed guidance and commentary on sales performance of key assets and new product launches, however, I have completed sales projections for AbbVie to 2030, which I will share in this post, highlighting areas of strength and potential weaknesses. For the next year, analysts predict that Free Cash Flow will reach 6.91B - an increase of 1.94%. You should never invest money you cannot afford to lose. Pharmaceuticals are often valued based on a philosophy of "jam tomorrow" as opposed to jam today i.e. We expect that to happen in 2027 with continued significant growth anticipated in the following years. The Immunology division looks strong, even factoring in the patent cliff faced by $20 billion-selling Humira. With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! (my table and forecasts). Sales are expected to recover in H2'22, however, and forecast year-on-year growth. How to Decide, Taiwan Semiconductor Manufacturing Expanding in the West, One Way to Earn More From Dividend Stocks, How to Choose a Winning Dividend Investing Strategy, 3 Industries Leading the Stock Market Rebound, Oil Tankers Boost Dividends, See Continued Robust Business In '23. These products are not suitable for everyone and you should therefore consider your objectives, financial situation, needs and experience with these products before investing in them. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. The development of these 2 drugs has been very quick by drug development standards, and to date both have performed exceptionally well. What guidance has AbbVie issued on next quarter's earnings? In the last two years, GSK's Free Cash Flow has grown by 0.37%, rising from 6.76B to 6.78B. As we can see the immunology division consists of only 3 assets yet by my calculation, will likely account for 50% of AbbVie's revenues in 2022 (to calculate 2022 sales revenues by product, since we do not yet have final figures, I have used 9m 2022 figures and assumed Q4 revenues will be the average of the previous 3 quarters). Investors do not seem to be taking the bait, however, as AbbVie's share price has slipped by >7% across the past month, and >5% across the past 5 days. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tbbi lalar Sanayi ve Ticaret Limited irketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundacin AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC. The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. Disclosure: I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. ABBV currently yields 4.1% and has raised its dividend every year since 2013. AbbVie could be the biggest global Pharma by revenue generation in 2028. Other products such as Mavyret and Creon appear to have many more years of blockbuster sales ahead of them, although it is interesting to note that AbbVie no longer reports revenues from its Women's Health division, and scarcely mentions it. The company had recorded a $4.7 billion increase in the contingent consideration liability related to Skyrizi last year. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth New research suggests Depakote ingredient could have a new clinical function. In my last note on AbbVie (NYSE:ABBV) for Seeking Alpha - in early July - I reviewed the Big Pharma's Q1'22 earnings and looked ahead to the release of Q2'22 figures. Trial results demonstrated an overall response rate of 63% and a median duration of response of 12 months, where 39% of patients had already tried a CAR-T cell therapy. It now expects full-year profit in the range of $13.92-$14.12 a share. I have not managed to match management's ambitious high-single-digit growth figures from 2025 - 2023, despite anticipating 6% growth for nearly all products in that period. Although investing in AbbVie isn't riskless, it is advisable based on what we know about the company. With AbbVie's revenues accelerating past $80bn in 2030 (by my calculation), and cash flow generated in that year being >$25bn, after applying discount factors for each year I reach a price target of $176 - the average of DCF - $162 per share - and EBITDA - $189 per share - calculations. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most. Zscaler, Inc Plummets, Is It Time To Buy The Dip? Johnson & Johnson Free Cash Flow Forecast for 2023 - 2025 - 2030. According to 23 major analysts, AbbVie's Fair Value will fall by 5.43% in the next year, reaching $122.98. Slide from JPM Conference 2022 presentation. Below, I will outline how I see AbbVie putting the Humira LOE firmly behind it, and driving the high single digit percentage annual growth management has promised. What that means is, essentially it will be on formulary with biosimilars, but there won't be any difference between the biosimilar and Humira from a co-pay standpoint or any kind of a step editing. Having dived into the numbers however and looked ahead to 2030 through the eyes and guidance of management, my conclusion is that investors can probably buy AbbVie stock at current price with reasonably high hopes of making a decent ROI - perhaps 15 - 20% in the next 12 - 18 months, whilst also benefiting from a generous dividend. Epcoritamab alone will not be sufficient to get AbbVie where it wants to be - despite some analysts believing it will be the highest grossing Pharma revenue wise by 2026. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. My EPS figure increases slightly between 2022 and 2023, whilst AbbVie has suggested it will be down slightly before beginning to accelerate towards the end of the decade, as revenues correspondingly begin to climb sharply once the worst of the Humira LOE is over. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. According to the Abbvie stock technical analysis, as of 30 June, the Relative Strength Index (RSI) was pointing to neutral at 62.18. I am not receiving compensation for it (other than from Seeking Alpha). AbbVie income statement forecast (My table and assumptions). Shareholders of record on Friday, April 14th will be given a dividend of $1.48 per share on Monday, May 15th. According to CEO Gonzalez: Over the long-term, aesthetics continues to be an extremely attractive underpenetrated market with significant growth potential. The other major plus is probably the performance of the neuroscience divisions, where as we can see, Botox (indicated for migraine treatment), atypical antipsychotic Vraylar, migraine therapy Ubrelvy and newly launched Qulipta, an oral CGRP inhibitor indicated for chronic migraine all delivered good sales growth. Forecasts shouldnt be used as a substitute for your own research. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABBV, but not buy additional shares or sell existing shares. Aesthetics was propped up by growing sales of Botox - up 12% year-on-year to $678m, but let down by sales of Juvederm, which management put down to lockdown regulations in China, and the "suspension" of operations in Russia. The average price target is $163.64 with a high forecast of $190.00 and a low forecast of $133.00. On average, analysts forecast that ABBV's EPS will be $11.80 for 2023, with the lowest EPS . There are still very few approved therapies, although that could change with Crispr Therapeutics (CRSP) / Vertex (VRTX) Sickle Cell Disease therapy leading the charge in 2023. After 2022 Humira's row is shaded yellow to signify patent expiry. Out of the most recent ratings, BMO Capital Markets Gary Nachman raised its price target from $161 to $174 with an outperform rating, while Truist Financial analyst Robyn Karnauskas raised the Abbvie stock prediction from $118 to $135 while raising rating to a buy. The most recent increase was . View ABBV analyst ratings or view top-rated stocks. I am not receiving compensation for it (other than from Seeking Alpha). That was below AbbVie stock analysts' view for $14.16. AbbVie, like its parent Abbot Laboratories, is a well-established dividend growth stock. Thus, it is likely that ABBV will continue to find support on the dips in this type of market environment.. How do I arrive at my share price target? 1 dividend stock for a LIFETIME of income. z o.o., AbbVie Productos Farmacuticos Limitada, AbbVie Products LLC, AbbVie Promoo L.da, AbbVie Pte. The average ABBVIE INC stock forecast 2023 represents a 1.86% increase from the last price of $153.729995727539. Trading CFDs is high risk and is not suitable for everyone. And with a dividend yield of 4.9%, AbbVie is quite attractive for investors yearning for . What is the dividend yield for AbbVie? The review period was extended by three months in order for the FDA to review additional data submitted by AbbVie. AbbVie passed that onto its 2022 guidance. Always conduct your own due diligence before investing. According to the algorithm-based forecaster Wallet Investor in its Abbvie stock forecast for 2022, the price could reach $169.852 by the end of December, $199.491 by 2023 and $229.304 by 2024. I suspect Eye Care is a division AbbVie can turn around given time, and I feel that with regards to oncology, where AbbVie has the strongest pipeline assets - lymphoma bispecific Epcoritamab may be approved to treat large B-cell lymphoma, and peak sales estimates range from $1.5 - $3bn, although AbbVie will not earn all of that since the product is co-developed with Genmab. The company provided earnings per share (EPS) guidance of $10.70- for the period. All rights reserved. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community. AbbVie has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. The stocks growth marks a significant outperformance over the broader markets. ABBV-916 is targeting Alzheimer's and it is an anti-amyloid antibody, with a similar mechanism of action ("MoA") to recently approved Leqembi, developed by Biogen (BIIB) / Eisai, and likely soon-to-be approved Donanemab, developed by Eli Lilly. Drug development has not traditionally been one of AbbVie's strengths - it has not had to be - but we ought to see the positive results of heavy investment into the oncology pipeline over the next 5-7 years, and by 2030, I believe this division could account for >17% of AbbVie's total revenues. Read our dividend analysis for ABBV. With a 5-year investment, the revenue is expected to be around +88.28%. The acquisition expanded AbbVies neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies. I have no business relationship with any company whose stock is mentioned in this article. AbbVie's free cash flow yield is 10.5% compared to 4.3% for Johnson & Johnson . The Large Pharma sector performed remarkably well in 2022, with the "Big 8" delivering an average ~15% gain whilst the S&P 500 index fell in value, and the biotech sector was in turmoil. In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Our Product Disclosure Statement (PDS) and Target Market Determination provides important information about our products and who our products are more likely to be suited to Capital.com does not provide financial or investment advice and you should seek independent advice if you are unsure of the risks or whether our products are suitable for you. Please log in to your account or sign up in order to add this asset to your watchlist. If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth. In terms of market cap, it ranks third behind Pfizer ( PFE) and Novo Nordisk ( NVO ). AbbVie probably does not want to be recognized as simply an immunology giant however, it wants to be substantially more diversified and like all major Pharma's it has a strong long-term focus on oncology. Projections are based on making fundamental and technical studies of the ABBV stock price performance. Drug pricing is another issue - there is bipartisan, and international pressure on US Pharmas to reduce drug pricing, particularly outside of the US. The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023. Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents, Timothy J Richmond and Timothy J Richmond. Within eye care, Restasis was a major disappointment, and the entire division seems to be struggling, with total revenues falling from ~$920m in Q2'21, to ~$720m in Q2'22. In summary, the total revenue increase of just 4% year-on-year in Q2'22 might disappoint a few investors, as might the downgraded guidance, although it is hard to argue that AbbVie is a bad investment when we consider that the Pharma also pays a dividend of $1.41 per quarter, yielding 4% per annum, drove operating earnings of $3.925bn on a GAAP basis, and trades at a >10% discount to my calculated target price. outlook for a company that is still only 10 years old and is about to feel the impact of a loss of patent protection for its mega-blockbuster auto-immune drug Humira, which made $20.7bn of sales for the company in FY21, representing 37% of total revenues generated. The material provided on this website is for information purposes only and should not be understood as an investment advice. Please disable your ad-blocker and refresh. But AbbVie is also keen to explore solid tumors, and I am therefore adding an additional $1.5bn of revenues from that source by 2030. Move your mouse over a quarter or year to see how estimates have changed over time. 164.71 0.00 0.00%. The surge in revenues can primarily be attributed to its Allergan. As we can see, as per management's guidance revenues fall between 2022 and 2023, before recovering and growing in each year after. I write about Biotech, Pharma and Healthcare stocks and share investment tips. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. This included an unfavourable impact of $0.08 a share related to acquired in-process research and development (IPR&D) and milestones expenses incurred during the March quarter.
Snow Evelyn Robin Juliet Gibb Claire Yang,
Motorola Si500 Software,
Williamsport High School Baseball,
A Million Little Things Eddie Walk Again,
Articles A